Tuberculosis News and Research

Latest Tuberculosis News and Research

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

In a speech delivered at the XIX International AIDS Conference in Washington, D.C., on Monday, U.S. Secretary of State Hillary Clinton "underscored the United States' commitment to achieving an 'AIDS-free generation' and announced more than $150 million in additional funding," Politico reports.

25 Jul 2012

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

A selection of editorials and op-eds from around the country that focus on the campaign to eradicate HIV.

25 Jul 2012

Recent release: Global Fund results show 3.6M people on HIV treatment under fund-supported programs

In a round-up of events from the XIX International AIDS Conference on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Trevor DeWitt, new media communications officer for the foundation, notes that the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday released results "showing broad gains in the number of people receiving HIV treatment."

24 Jul 2012

Novel combination drug regimen could be more effective than existing treatments for TB

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet.

24 Jul 2012

First results from community HIV testing campaign in Uganda

A clinical study in a remote region of southwest Uganda has demonstrated the feasibility of using a health campaign to rapidly test a community for HIV and simultaneously offer prevention and diagnosis for a variety of other diseases in rural and resource-poor settings of sub-Saharan Africa.

24 Jul 2012

New FDA guidelines on HIV And TB drug doses may not apply to African and Asian patients

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.

24 Jul 2012

First Edition: July 24, 2012

Today's headlines include news from the campaign season as well as reports from the international AIDS conference currently taking place in Washington, D.C.

24 Jul 2012

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

Warner C. Greene, MD, who directs virology and immunology research at the Gladstone Institutes, has joined with other global AIDS experts to release a locally affordable version of the world's leading AIDS medical textbook. Designed specifically for regions that today are hardest hit by the disease, this new text is the latest weapon in a growing arsenal aimed at curbing the spread of HIV/AIDS worldwide.

24 Jul 2012

TB combination drug trials progress

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.

24 Jul 2012

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

On the eve of the XIX International AIDS Conference in Washington, DC, the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, announces a new collaboration with Indian drug manufacturer Cipla to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS.

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

Examining challenges facing Global Fund during its reform

Optimism surrounding the science of HIV treatment and prevention "is tempered by less auspicious trends, particularly shrinking budgets for global health in the U.S. and around the world," Victoria Fan, Amanda Glassman, and Rachel Silverman of the Center for Global Development (CGD) write in the center's "Global Health Policy" blog.

20 Jul 2012

Keystone Symposia on Molecular and Cellular Biology receives Gates Foundation grant

Keystone Symposia on Molecular and Cellular Biology is pleased to announce that it has received a fourth grant from the Bill & Melinda Gates Foundation to promote discoveries that will solve urgent global health problems via support of infectious disease conferences in the "Keystone Symposia Global Health Series."

20 Jul 2012

Donor nation funding for HIV remains at 2008 levels, Kaiser Family Foundation/UNAIDS analysis says

A funding analysis released on Wednesday by the Kaiser Family Foundation (KFF) and UNAIDS found that "funding to fight HIV/AIDS in low- and middle-income countries has remained flat at $7.6 billion," Politico Pro reports.

20 Jul 2012

Better methods needed to diagnose and treat HIV, TB in children

Jennifer Furin, an infectious diseases physician and medical anthropologist who specializes in the management of tuberculosis (TB) and HIV in resource-poor settings, writes in a post in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog that "when it comes to the great advancements made in global HIV and TB care, children are being left behind."

19 Jul 2012

Africa's new partnership for sustainable health development 'makes sense'

With Africa's "emerging position in the global order, ... astute African leaders are striving to ensure that this realignment delivers a new paradigm of partnership for sustainable health development -- a partnership that is led by Africa, for Africans, through African-sourced solutions," UNAIDS Executive Director Michel Sidibe writes in a Huffington Post "Impact Blog" opinion piece.

19 Jul 2012

Tuberculosis News and Research

Latest Tuberculosis News and Research

New combination therapy for TB shows promise in Phase II study

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

Recent release: Global Fund results show 3.6M people on HIV treatment under fund-supported programs

Novel combination drug regimen could be more effective than existing treatments for TB

First results from community HIV testing campaign in Uganda

New FDA guidelines on HIV And TB drug doses may not apply to African and Asian patients

First Edition: July 24, 2012

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

TB combination drug trials progress

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

New CHAIT initiative on development of novel immunological therapeutic interventions

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Study explores role of L. reuteri against foodborne infection

Examining challenges facing Global Fund during its reform

Keystone Symposia on Molecular and Cellular Biology receives Gates Foundation grant

Donor nation funding for HIV remains at 2008 levels, Kaiser Family Foundation/UNAIDS analysis says

Better methods needed to diagnose and treat HIV, TB in children

Africa's new partnership for sustainable health development 'makes sense'

Innovation in neuroscience drug discovery - eBook eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Tuberculosis News and Research

Latest Tuberculosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in